Skip to main content
GENEDRIVE PLC logo

GENEDRIVE PLC — Investor Relations & Filings

Ticker · GDR ISIN · GB00B1VKB244 LEI · 213800ZYODIRZ87Y4K14 IL Manufacturing
Open in API
Filings indexed 606 across all filing types
Latest filing 2022-10-24 Remuneration Information
Country GB United Kingdom
Listing IL GDR

About GENEDRIVE PLC

https://genedriveplc.com/

Genedrive PLC is a molecular diagnostics company specializing in the development and commercialization of a rapid, point-of-care pharmacogenetic testing platform. The company's core technology, the Genedrive® System, is designed for the swift diagnosis of genetic variants to enable personalized medicine in critical care settings. Its key products include the Genedrive® MT-RNR1 ID Kit, used to prevent antibiotic-induced hearing loss in infants, and the Genedrive® CYP2C19 ID Kit, which helps optimize antiplatelet therapy for stroke patients. The platform empowers clinicians to make safer and more effective treatment decisions by providing crucial genetic information at the point of need, thereby improving patient outcomes.

Recent filings

Filing Released Lang Actions
Grant of options
Remuneration Information Classification · 1% confidence The document is an official announcement disseminated via RNS (RNS Number: 7697D) from Genedrive PLC on October 24, 2022. The content explicitly details the 'Grant of Options' to senior management, including names, positions, number of options, exercise price, and vesting conditions. Crucially, it states that the information is provided in accordance with Article 19(3) of the EU Market Abuse Regulation (MAR), which mandates disclosure of transactions by Persons Discharging Managerial Responsibilities (PDMRs). This type of insider transaction disclosure (grant of options to directors/executives) falls under the category of Director's Dealing (DIRS). Although it involves management, it is a specific transaction report, not a general management change (MANG) or remuneration report (DEF 14A). Since it is a specific regulatory disclosure about insider transactions, DIRS is the most appropriate code.
2022-10-24 English
Second Price Monitoring Extn
Share Issue/Capital Change Classification · 1% confidence The document is very short (1930 characters) and contains the header 'RNS Number : 9329B'. It announces a 'Second Price Monitoring Extension' related to trading activity on the London Stock Exchange. It explicitly states, 'This information is provided by RNS, the news service of the London Stock Exchange.' This indicates it is a general regulatory announcement disseminated via the RNS system, rather than a specific financial report like an ER, IR, or 10-K. Since it is a general regulatory announcement that doesn't fit the specific categories (like DIRS, DIV, or DLST), the most appropriate fallback category is Regulatory Filings (RNS).
2022-10-05 English
Price Monitoring Extension
Share Issue/Capital Change Classification · 1% confidence The document is very short (1913 characters) and contains the header 'RNS Number : 9314B' and mentions 'RNS, the news service of the London Stock Exchange' and 'Financial Conduct Authority'. The content describes a 'Price Monitoring Extension' for a security, which is a specific, non-standard operational announcement related to trading mechanics, not a core financial report (like 10-K, IR, or ER). Since it is a regulatory announcement that doesn't fit the specific categories like DIRS, DIV, or CAP, and it is clearly branded as an RNS release, the most appropriate classification is the general Regulatory Filings category (RNS). It is not an announcement of a report publication (RPA) because it is reporting an event (price monitoring extension), not announcing the release of a separate document.
2022-10-05 English
US FDA pre-submission for Genedrive MT-RNR1 kit
Regulatory Filings Classification · 1% confidence The document begins with 'RNS Number : 7594B' and concludes with standard disclaimers from 'RNS, the news service of the London Stock Exchange'. The content announces a specific corporate action: filing a US FDA Pre-Submission for a product. This is a typical regulatory announcement made via the RNS system. Since it is a general regulatory announcement that doesn't fit into specific categories like Director's Dealing (DIRS), Earnings Release (ER), or Capital Change (SHA), the most appropriate classification is the general Regulatory Filings category (RNS). The document length is moderate (5189 chars), but the nature of the content is a direct announcement of regulatory progress, not a detailed report itself.
2022-10-05 English
NICE to accelerate evaluation of Genedrive test
Regulatory Filings Classification · 1% confidence The document is a formal announcement disseminated via RNS (Regulatory News Service) from Genedrive PLC on September 26, 2022. It details an administrative update regarding the evaluation process of one of their diagnostic tests (Genedrive® MT-RNR1 Test) by NICE, specifically mentioning a transfer to a new 'Early Value Assessment Programme' (EVA) and providing timelines for future reports. The text is short, contains contact information, and concludes with standard RNS disclaimers. It is not a full financial report (10-K, IR), an earnings release (ER), or a presentation (IP). Since it is a general, time-sensitive regulatory announcement that doesn't fit into the more specific categories like Director's Dealing (DIRS) or Dividend Notice (DIV), the most appropriate classification is the general regulatory announcement category, RNS.
2022-09-26 English
NICE includes CYP2C19-ID Kit in new programme
Regulatory Filings Classification · 1% confidence The document starts with an 'RNS Number' and is dated August 22, 2022. It announces that NICE has included Genedrive's CYP2C19-ID Kit in a new Diagnostics Assessment Programme (DAP). This is a general announcement regarding company news, product development inclusion in a regulatory/assessment process, and includes contact information typical of a regulatory news service release. It is not a full financial report (10-K, IR), an earnings release (ER), a management discussion (MDA), or a proxy statement (DEF 14A/PSI). Since it is a general regulatory announcement distributed via RNS and does not fit into the more specific categories like Director's Dealing (DIRS) or Capital Change (CAP), the most appropriate classification is the general Regulatory Filings category (RNS). The document length is moderate (5801 chars), but the content is purely informational news, not the detailed report itself.
2022-08-22 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.